JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 6, 2005; DOI: 10.1124/jpet.105.083980


0022-3565/05/3141-70-76$20.00
JPET 314:70-76, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.083980v1
314/1/70    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henry, J. C.
Right arrow Articles by Cardounel, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henry, J. C.
Right arrow Articles by Cardounel, A. J.

CARDIOVASCULAR

Inhibition of Ribonucleotide Reductase Reduces Neointimal Formation following Balloon Injury

Jon C. Henry1, Mary M. Bonar1, Patrick N. Kearns, Hongmei Cui, Megan M. Mutchler, Michael V. Martin, Anthony R. Orsini, Howard L. Elford, Charles A. Bush, Jay L. Zweier, and Arturo J. Cardounel

Davis Heart and Lung Research Institute and the Departments of Pharmacology (J.C.H., M.M.B., P.N.K., M.M.M., M.V.M., A.J.C.) and Internal Medicine (H.C., A.R.O., C.A.B., J.L.Z.), The Ohio State University College of Medicine, Columbus, Ohio; and Molecules for Health, Inc., Richmond, Virginia (H.L.E.)

Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded coronary arteries, but its benefits have been undermined by a high incidence of restenosis. The introduction of coronary stents has significantly improved the short and long term outcome but restenosis still occurs in approximately 15 to 30% of patients within 6 months. Research efforts are now being directed toward combination stenting and drug delivery. Among the therapeutic targets being pursued are agents that can impede smooth muscle cell migration and proliferation, as these processes are critical components of restenosis injury. We propose that inhibiting the conversion of ribonucleotides to deoxyribonucleotides will impede cell proliferation and, as such, limit the degree of restenosis. Therefore, we tested whether the potent ribonucleotide reductase inhibitors Didox (3,4-dihydroxybenzohydraxamic acid) and Imidate (ethyl-3,4,5-hydroxybenzimidate) can limit the neointimal proliferation associated with restenosis using a rat carotid model of balloon dilatation injury. Results demonstrated that both Didox and Imidate significantly reduced intimal thickening, resulting in a 71 and 62% decrease in the intima/media ratio, respectively. Similar efficacy was seen with the commercially available ribonucleotide reductase inhibitor hydroxyurea, demonstrating the importance of this enzyme in vascular remodeling. Results from cell proliferation studies suggest that the mechanism of protection is inhibition of smooth muscle cell (SMC) proliferation. In addition, Didox and Imidate (100 µM) are potent inhibitors of SMC migration, which may also contribute to their vascular protective effects. These results suggest that inhibition of ribonucleotide reductase may provide a potent strategy to prevent post-PTCA restenosis.


Received January 26, 2005; accepted March 31, 2005.

Address correspondence to: Arturo J. Cardounel, Davis Heart and Lung Research Institute, 473 W. 12th Ave., Columbus, OH 43210. E-mail: cardounel-1{at}medctr.osu.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.